Intestinal Health Formula & Anti-Inflammatory | OraMune

Egg Yolk Anti Tumor Necrosis Factor (IgY) Antibody Plus Bovine Lactoferrin:

umor necrosis factor alpha (TNF) is a pro-inflammatory cytokine implicated in the pathogenesis of Crohn’s disease, chronic recurrent inflammatory bowl disease (IBD), ulcerative colitis and certain other autoimmune disorders. Lactoferrin is a bactericidal, natural immune modulator widespread among various biological fluids. The therapeutic role of lactoferrin and its effect on TNF and other proinflammatory cytokines were studied in experimentally induced colitis in rodents. Oral administration of both human and bovine lactoferrin significantly reduced inflammation, TNF and other inflammatory cytokine levels in the rodent’s colonic tissues. Lactoferrin therefore exerts a protective effect against colitis in rodents via modulation of the immune system and correction of cytokine imbalance.

Another approach to the therapy of colitis, IBD and TNF associated inflammatory disease is neutralization of TNF by specific antibodies. A number of monoclonal antibodies are currently available for therapy of these diseases, however, recently concerns have been raised regarding repeated intravenous infusions, adverse side effects and very high cost of treatment. Ora Mune Intestinal Health Formula is an orally delivered combination of lactoferrin and egg yolk anti TNF (IgY) antibody, two natural safe and potent anti TNF products that may be useful in neutralizing gut associated proinflammatory cytokines and restore colon health.


  1. Worledge KL, Godiska R, Terrance A. et al. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Digestive Disease and Sciences. 45:2298-2305, 2000.
  2. Ganesan S, Travis SP, Ahmad T, Jazarawi R. Therapeutic inhibitors of tumor necrosis factor in Crohn’s disease. Curr. Open Invsetig. Drugs. 3:1301-1306, 2002
  3. Mamula P, Cohen SA, Ferry GD et al. CDP51, a humanized anti tumor necrosis factor alpha monoclonal antibody in pediatric Crohn’s disease. Inflam. Bowl Dis.10: 723-730, 2004.
  4. Holtmann MH, Neurath MF. From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowl disease. Adv. Exp. Med. Biol. 579: 227-242, 2006.
  5. Haversen LA, Baltzer L, Dolphin G. et al. Anti inflammatory activities of human lactoferrin in acute dextran sulphateinduced colitis in mice. Scand J. Immunol. 57: 2-10, 2003.
  6. Tagawa J, Nagase H, Tanak K. et al. Oral administration of lactoferrin reduces colitis via modulation of immune system and correction of cytokine imbalance. J. Gastroenterol. Hepatol. 17: 1291-1298, 2002